NCT06915701View on ClinicalTrials.gov

"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

June 15, 2025

Study Completion Date

December 15, 2027

Conditions
Rheumatoid Arthritis
Interventions
DIETARY_SUPPLEMENT

Will take vitamin E 800mg/day

Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.

DRUG

Will take 200mg/day magnesium oxide placebo.

Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.

Trial Locations (1)

44340

Universidad de Guadalajara, Guadalajara

All Listed Sponsors
collaborator

Civil Hospital of Guadalajara

UNKNOWN

lead

University of Guadalajara

OTHER

NCT06915701 - "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" | Biotech Hunter | Biotech Hunter